ABL1 and pericardial effusion: The last-generation BCR-ABL TKI bosutinib may cause hypertension, as well as pleural and pericardial effusion, while ponatinib, 3rd generation BCR-ABL TKI may cause hypertension (10%), atrial fibrillation, heart failure, hyperglycemia, dyslipidemia, pericardial or pleural effusion, and vascular toxicity (1–10%).